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METHODS
Patient selection
Patients who underwent catheter ablation for VT from January 2012 to January 2018 were prospectively entered into a registry. Patients were referred from University Hospital Coventry and surrounding centres. All adult patients (≥ 18years) were listed having been discussed at an arrhythmia multidisciplinary team meeting. For nhVT referral criteria included symptomatic VT despite medical therapy, intolerance to medication or patient preference against medication, significant (>10%) premature ventricular complex (PVC) burden with symptoms or without symptoms and cardiac dysfunction. For structural heart VT (shVT) indications included symptomatic VT despite medical therapy, three or more episodes of VT within 24 hours, at least 3 episodes of VT requiring anti-tachycardia pacing (ATP) or at least one defibrillator shock. All patients provided written consent prior to the procedure. Approval for the study was provided by our Local Audit and Research Department. The study applied the principles of the declaration of Helsinki.
All patients had transthoracic echocardiography and/or cardiac magnetic resonance imaging prior to the procedure to evaluate ventricular function, scar burden and intracardiac thrombus assessment. nhVT was defined as structurally normal heart (on echocardiogram or cardiac magnetic resonance imaging), or patients with cardiac dysfunction attributed to high PVC burden (defined as >10%). shVT included patients with ICM or non-ischaemic cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyopathy or cardiomyopathy due to valvular heart disease).
Procedure details
All procedures were performed at the University Hospital Coventry. otherwise VT was terminated with ATP or electrical direct current cardioversion.
Anticoagulation strategy
Oral anticoagulation with warfarin was uninterrupted (target international normalised ratio 2.0-3.0). Direct oral anticoagulants were omitted on the day of the procedure. Following successful trans-septal puncture intravenous heparin was administered to maintain an activated clotting time >300s. At the end of the procedure protamine (50mg over 10min) was administered and anticoagulation resumed the same day provided there were no significant bleeding events.
Mapping and ablation
Electro-anatomical substrate and activation mapping was performed using the Ensite NAVX/Velocity/Precision (Abbott Medical, Inc., Minneapolis, MN) systems or CARTO 3 (Biosense-Webster, Inc., Diamond Bar, CA). All nhVT cases underwent pace mapping and if VT was haemodynamically stable, activation mapping was performed. A successful pace map was defined as QRS morphology match in at least 11 of 12 leads. 1 In patients with SHD a combination of substrate mapping (bipolar signal amplitude <1.5 mV as scar and <0.5 mV as dense scar), pace mapping (with a stimulation to QRS>45ms) and activation/entrainment mapping were performed, as shown in Figure 1 . The critical isthmus, late potentials, local abnormal ventricular activities (LAVA) potentials and decrementing early/late potentials were identified. 2, 3 Unstable VT mapping and ablation were performed in sinus or paced rhythm using a substrate modification approach. [4] [5] [6] [7] Catheter mapping and ablation was performed using a range of catheters including conventional and saline-irrigated ablation catheters (≤8mm tips) ( Supplementary Table 1 ). Power, force-time integral, lesion size index and ablation index settings were at the operator's discretion. At the end of the procedure standardised PES was performed. Complete acute procedural success was defined as termination of clinical VT with failure to induce clinical VT or VT with a longer tachycardia cycle length (TCL). To minimise follow up bias, postprocedure ICD therapies (ATP and shock) were programmed according to a standardised protocol on the basis of the best evidence available. 8, 9 Outcomes Follow up was taken as the last documented clinical contact with the patient after the VT ablation including last clinic consultation and/or ICD interrogation. In the case of re-do procedures follow-up time was calculated from the first procedure performed and comparative outcomes were determined after the first procedure.
The primary outcome for nhVT was a composite endpoint including all cause death, cardiovascular hospitalization and recurrent VT (defined as spontaneous sustained Values expressed as mean±SD for continuous variables and frequency (%) for discrete variables unless otherwise specified. Group differences were tested using Chi-squared test and Independent t test for discrete and continuous variables respectively. For non-normally distributed data the Mann Whitney U Test was used to test group differences. a n=18 IQR = interquartile range, RF = radiofrequency, VT = ventricular tachycardia. 
